High-Dose Vitamin D3 Supplementation

Summary

High-dose vitamin D3 supplementation (above 2,000 IU/day) shows meaningful benefits for depression, autoimmune disease prevention, and potentially respiratory infections. The landmark VITAL trial found that 2,000 IU daily reduced autoimmune disease risk by 22% over 5 years, while multiple meta-analyses show small-to-moderate effects on depression symptoms. Some practitioners use extremely high doses (40,000+ IU/day) for autoimmune conditions with promising anecdotal results, but this requires strict medical supervision and monitoring.

The evidence is moderate-to-strong for standard high doses (2,000-5,000 IU/day), which are safe for most people. Very high doses show intriguing potential but lack rigorous clinical trial confirmation and carry risks if not properly monitored.

Why Moderate

Tier 2 because the depression evidence is meta-analytically supported (effect sizes -0.32 to -0.40 across multiple analyses, dose-dependent above 2,000 IU/day in deficient populations) and the VITAL trial provides landmark evidence for autoimmune disease prevention (n≈26,000, 22% reduction in incident autoimmune disease over 5.3 years on 2,000 IU/day, NNT ~30). Mechanism is hormone-like — 200+ genes regulated, including immune function, neurotransmitter synthesis, inflammation. Tier 3 for respiratory infection prevention (mixed results, recent meta-analysis of 46 trials found only borderline significance) and Tier 4 specifically for Coimbra-protocol mega-dosing (40,000–300,000 IU/day claims of 95% MS suppression lack RCT confirmation). Safety: ≤10,000 IU/day generally safe, toxicity typically only above 50,000 IU/day extended. Not Tier 1 because dose-response specificity beyond deficiency-correction is less precisely characterised.

Tier 2 for standard high-dose; Tier 3 for respiratory infection; Tier 4 for Coimbra mega-dosing

Practical takeaway

Most people benefit from 2,000-5,000 IU/day of vitamin D3, especially those with limited sun exposure, depression symptoms, or autoimmune disease risk. Take it with a fat-containing meal and consider adding vitamin K2. Test your blood levels (aim for 40-60 ng/mL) after 3 months, then annually. Higher doses require monitoring of blood calcium levels. If you're interested in very high doses for autoimmune conditions, work with a physician familiar with these protocols.

Key findings

2,000 IU/day for 5+ years reduces autoimmune disease incidence by 22% in adults over 50
Depression symptoms improve with vitamin D supplementation, with stronger effects at doses above 2,000 IU/day
Respiratory infection prevention shows small benefits, particularly for influenza and COVID-19 in some studies
Doses up to 10,000 IU/day appear safe for most people when monitored appropriately
Mega-dosing protocols (40,000+ IU/day) show remarkable anecdotal results for autoimmune conditions but require medical supervision

Evidence detail

Vitamin D functions more like a hormone than a vitamin, regulating over 200 genes involved in immune function, neurotransmitter synthesis, and inflammation. This explains why higher doses show benefits beyond bone health.

The depression evidence is particularly strong, with multiple meta-analyses showing small-to-moderate effects (effect sizes of -0.32 to -0.40). The benefit appears dose-dependent, with stronger effects above 2,000 IU/day and in people with baseline deficiency. One dose-response analysis found each additional 1,000 IU/day yielded meaningful symptom improvement.

For autoimmune disease prevention, the VITAL trial provided landmark evidence. This large randomized controlled trial of nearly 26,000 adults found 2,000 IU/day reduced incident autoimmune diseases like rheumatoid arthritis and psoriasis by 22% over 5.3 years. The number needed to treat was approximately 30 people over 5 years.

Respiratory infection prevention shows more mixed results. While earlier studies suggested benefit, the most recent meta-analysis of 46 trials found only borderline significance for general respiratory infections. However, subgroup analyses suggest stronger effects for influenza specifically and in deficient populations.

The most controversial area involves mega-dosing protocols like the Coimbra Protocol, which uses 40,000-300,000 IU/day for autoimmune diseases. Proponents report remarkable success rates (95% disease suppression in multiple sclerosis), but these claims lack randomized controlled trial confirmation. The protocol requires strict medical supervision, low-calcium diets, and regular monitoring to prevent hypercalcemia.

Safety data suggests doses up to 10,000 IU/day are generally safe, with toxicity typically occurring only above 50,000 IU/day for extended periods. However, individual variation exists, and monitoring becomes important at higher doses.